Posted by Michael Wonder on 15 Aug 2024
FDA approves neo-adjuvant/adjuvant durvalumab for resectable non-small cell lung cancer
15 August 2024 - Today, the FDA approved durvalumab (Imfinzi, AstraZeneca) with platinum-containing chemotherapy as neo-adjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
Efficacy was evaluated in AEGEAN, a randomised, double-blind, placebo-controlled multi-centre trial in 802 patients with previously untreated and resectable squamous or non-squamous non-small cell lung cancer (stage IIA to select stage IIIB [AJCC, 8th edition]).
